For Patients

Simplifying access to comprehensive UTI care

Biotia, in partnership with Clinova Solutions, has created a full service care pathway for patients managing challenging UTIs.

What it is

At-home UTI testing and treatment

The standard of care for UTI patients is flawed. The tests most providers use miss important pathogens. Clinical expertise in diagnosing and treating patients with complex UTI histories is difficult to find. For many patients navigating challenging UTIs, the prospect of finding relief can feel bleak.

Advanced, at-home diagnostic testing

Telehealth from UTI specialists

Treatment and follow-up care made easy

Advanced, at-home diagnostic testing

Telehealth from UTI specialists

Treatment and follow-up care made easy

BIOTIA-ID Urine

Built for challenging UTI cases

The BIOTIA-ID Urine Test is a clinical metagenomic-based diagnostic test that outperforms standard urine culture. It is available for at-home collection across all 50 U.S. states.

Highlights

Identifies 44 pathogens, including bacteria and fungi
Detects pathogens often missed by standard urine culture
Drug resistance profiling included to guide targeted treatment

What is clinical metagenomics?

See how next-generation sequencing is changing the way urinary tract infections are diagnosed and treated.

Learn more

Comparison

The BIOTIA‑ID Urine Test

The BIOTIA-ID Urine Test outperforms standard urine culture and offers enhanced insights as compared to other next-generation sequencing (NGS)-based testing options.

View pathogens

Comparison of BIOTIA-ID with alternative testing approaches
	BIOTIA-ID Urine	NGS Competitors	Standard care
Test type	Clinical metagenomics	16s sequencing	Standard urine culture
Results turnaround	2–3 business days	2–5 business days	2–5 business days
Price	$249	$259	Varies
Resolution and detail	Detailed — species or strain level resolution	Poor — genus or species, with some groups unresolved	Detailed — genus or species for species that grow
Kinds of microbes	Extensive — bacteria, fungi, anaerobes, fastidious, and atypical pathogens	Limited — bacteria only	Limited — common bacteria and fungi only
Accuracy	High — limited contamination and false positives	Low — high potential for contamination and false positives	Low — high potential for contamination and false negatives
Percent of genome considered	Extensive — thousands of genes across the entire genome	Low — looks at only one gene in a section of the genome	None, not applicable
Future biomarker and therapeutic insights	High	Low	None
Antimicrobial resistance prediction	High — clinically validated resistance reporting	None	Separate testing required
Clinical relevance	High — healthy microbes filtered from report	Low — reports non-pathogenic species	Low — misses pathogenic species

Evidence

Science you can trust

Performance: High accuracy for a breadth of pathogens

The BIOTIA-ID Urine Test has been extensively validated on clinical samples. It was validated to reliably detect 44 key UTI-causing pathogens and 16 drug resistance markers.

Sensitivity

Specificity

0Pathogens detected

0Drug-resistance markers

The Diagnostic Gap: A negative urine culture does not mean there is nothing there

In a retrospective study of 200+ symptomatic UTI patient samples that were negative by standard urine culture, the BIOTIA-ID Urine Test identified a causative pathogen in a majority of samples.

of culture-negative samples had a pathogen detected by our test

Pathogen detectedNone detected

The Treatment Gap: Knowing the pathogen changes the prescription

Among the patients with a pathogen detected by the BIOTIA-ID Urine Test, the empiric antibiotic chosen under standard care would not have worked in over two out of three cases.

of empiric prescriptions could have been improved

of prescriptions would have had no effect on the pathogen found

could have been de-escalated to a narrower-spectrum drug

Our telehealth partner